Turquoise AE Roles Pay $245K–$285K OTE After $40M Raise

The Round That Changes the Game

Turquoise Health closed a $40 million Series C, Business Wire reported, in March 2026, led by Oak HC/FT with Andreessen Horowitz, Adams Street Partners, Yosemite, Bessemer Venture Partners, BoxGroup, and Tiger Global returning — capital earmarked not for more data ingestion but for an enterprise sales motion and a product organization that can turn contract intelligence into workflow software. The round brings total capital to roughly $95 million, Simplify's data shows, and values the company at a level its investors say supports a shift from data vendor to operating system: trustworthy rates, AI‑embedded workflows, and connected pricing, contracting, and payments on a single platform. The company's own blog frames the raise as "exactly what we're building next": infrastructure for a more open, efficient healthcare marketplace.

The funding is not generic growth capital. It is earmarked for two specific levers: an enterprise sales motion built around the employer and life‑sciences segments, and the same product organization. Chief executive Chris Severn told the team the capital supports go‑to‑market expansion and growing the nearly 200‑person, fully remote workforce. The first‑party job board shows the machine already moving: three roles posted in the past week alone, all senior enterprise account executives segmented by buyer (Employer, Provider Sales, Life Sciences, and Payer), each carrying an on‑target earnings band. A Senior Manager/Principal for Provider RCM Business Development & Strategy and an Engineering Manager for Data Products are also listed with competitive bands.

This hiring pattern reveals the strategy. Turquoise now serves 300 enterprise organizations, including ten of the top‑25 health systems. Its platform ingests machine‑readable files (the massive JSON datasets CMS requires hospitals and payers to publish) and layers on Clear Rates for auditable payer‑provider rates, Contracts for AI‑parsed document search, and AskTQ to cut manual research from weeks to seconds. But the next revenue layer is not more data access. It is selling that intelligence into the contracting workflows of employers designing benefit plans and life‑sciences companies modeling drug‑price exposure. That requires sellers who speak the language of self‑funded employers and pharma contracting teams, and product managers who can translate pricing signals into software those buyers embed in their own systems.

The Series C also signals a market inflection. CMS fines have topped $100 million, Simplify found, since 2024, pushing hospital compliance above 34 percent, according to PatientRightsAdvocate.org, for the first time. CareJourney has commoditized raw MRF data with free public datasets. Price convergence is already dropping high rates 6.3 percent annually, Simplify's figures indicate. In that environment, the winner is not the company with the cleanest data feed — it is the company that makes the data executable inside a contract negotiation, a formulary decision, or a patient‑facing estimator. Turquoise's hiring plan is a bet that the operating‑system layer is where the margin lives, and that the talent to build it must be hired now, before the next compliance deadline forces every buyer to choose a platform.

Four Sales Motions, One Playbook

The company's careers page shows four distinct Senior Enterprise Account Executive openings — each mapped to a different buyer segment. The roles carry identical compensation bands: that band with a 50/50 base-variable split, plus equity. That uniformity signals a deliberate strategy: the company is not hiring one "enterprise seller" and hoping for coverage; it is staffing four parallel motions (those segments) simultaneously.

The Employer-segment AE owns the full cycle from lead identification through contract finalization. The job description lists nine core responsibilities: identify new enterprise opportunities and develop them into high-value deals; build and maintain executive-level relationships with employers, brokers, and consultants; run discovery on ambiguous business problems and map them to Turquoise's contract-intelligence platform; own negotiations and procurement; collaborate with Product to feed customer insights back into the roadmap; maintain pipeline hygiene in Salesforce; forecast accurately; and hit quarterly revenue targets. The same posting requires five-plus years selling technology or management-consulting services, direct experience selling health-tech or data products to employers or brokers, and a track record of closing six- and seven-figure deals with C-suite stakeholders.

A separate listing for the Payer-segment AE mirrors the compensation and structure but swaps the buyer persona: the target is health-plan executives negotiating provider contracts and managing network adequacy. The Provider Sales AE focuses on health systems and physician groups that need to benchmark their own rates against competitors and comply with CMS machine-readable-file rules. The Life Sciences AE, a role that did not exist in Turquoise's org chart six months ago, sells into pharmaceutical and medical-device manufacturers that use price-transparency data to model market access, gross-to-net, and contracting strategy. Each role is remote-first, U.S.-based, and reports into the Enterprise Growth team.

Complementing the four AE slots, the board also shows a Senior Manager/Principal, Provider RCM Business Development & Strategy role at a competitive band. That position sits closer to partnership and channel development: it builds relationships with revenue-cycle-management vendors, clearinghouses, and consulting firms that embed Turquoise data into their own workflows. The split (four quota-carrying AEs plus one strategic BD lead) suggests the company expects direct sales to drive near-term ARR while the BD function compounds distribution over a longer horizon.

Qualifications across the AE roles are consistent: bachelor's degree or equivalent, comfort with Salesforce and modern sales stacks, and "domain expertise of the healthcare system in the United States and a curiosity to keep learning the intricacies and changes within the industry." The phrasing appears verbatim in all four postings, indicating a centralized hiring rubric rather than ad-hoc reqs. Turquoise's careers page adds that the team is "remote-first" and "values transparency, empathy, inclusivity, creativity, and ownership" — culture signals that matter when recruiting sellers who must navigate complex, multi-stakeholder deals without daily office oversight.

The employer segment is the newest revenue vector. Turquoise's platform historically served payers and providers; the Series C deck positioned employers as the next 300-plus-customer cohort. Hiring a dedicated Employer AE (rather than cross-selling from the payer team) acknowledges that buyer's distinct procurement cycle, compliance mandates (CA Transparency in Coverage, No Surprises Act), and decision-making unit (benefits leads, CFOs, broker consultants). The AE's mandate to "collaborate and share customer feedback with Product to identify new offerings" also feeds the life-sciences product push: employer demand for reference-based pricing tools and network-design analytics is shaping the very modules the Life Sciences PMs will build.

Building the Life-Sciences Engine

Turquoise Health's product hiring tells a clearer story than any press release. The company has two distinct product-management openings live right now: a Principal Product Manager, Life Sciences listed with a competitive salary band, and a Founding Product Manager, Life Sciences Workflows; both fully remote, both aimed at turning the pricing data layer into a workflow engine for pharmaceutical and medical-device manufacturers.

The Principal role sits at the center of the expansion. Whoever fills it will "lead the evolution of our Life Sciences suite of products" and own a roadmap that spans "complex pricing, modeling, and contracting workflows," the job description says. The mandate is explicit: design products that help life-sciences manufacturers commercialize their products, then extend those platform-level components into other verticals. That phrasing ("contribute platform-level components that scale to other verticals") signals the architectural ambition behind the hire. Turquoise isn't bolting on a life-sciences module; it's building a reusable contracting and modeling substrate that the rest of the product line can inherit.

The Founding Product Manager role carries a different weight. "Founding" in a 180-person, Series C company means this person defines the first version of a net-new product line (life-sciences workflows) rather than iterating an existing one. The description asks the hire to "continuously hone industry and subject matter expertise, staying ahead of market trends and legislative developments so Turquoise anticipates the tailwinds and headwinds in life sciences." That's a regulatory radar function baked into product. The CMS transparency rules that seeded Turquoise's hospital and payer data are now colliding with IRA drug-pricing provisions and state-level PBM reforms. A product manager who can map those moving targets into feature specs is the difference between a dashboard and a defensible workflow tool.

Both roles demand five-plus years of B2B health-tech product experience with a preference for contracting, document management, or financial modeling software. The Principal listing goes further: "deep Life Sciences commercial & reimbursement subject matter expertise," fluency with market-access, HEOR, and pricing-and-contracting stakeholders, and comfort navigating legal and compliance requirements for healthcare contracting. That's a rare hybrid — part data-platform PM, part life-sciences commercial-operations translator. Turquoise is betting that the scarce talent who speaks both languages will compound the value of its 300-plus enterprise customer base, which already includes payers, providers, and employers.

The technical bar matches the domain bar. The Principal PM must collaborate with engineers and data scientists on "data ingestion, structuring, normalization, and interpretation of complex healthcare data" and ensure "performance and product UX meet a high bar for clarity, accuracy, and explainability." Explainability matters because life-sciences customers (market-access leaders, field reimbursement managers) need to defend pricing decisions to internal finance teams and external regulators. A black-box model won't survive a CMS audit or a P&T committee review.

Turquoise's own careers page frames the mission as "eliminating the financial complexity of healthcare" and replacing "ambiguity with clarity, fragmentation with standardization, and opacity with transparency." The life-sciences product push is where that mission meets the hardest workflow in the industry — drug and device commercialization, where pricing, contracting, and evidence generation intersect. The two product managers they're hiring now will decide whether Turquoise becomes the operating system for that intersection or just another data vendor with a life-sciences slide deck.

How the Giants Are Moving

Optum Rx, the pharmacy benefit arm of UnitedHealth Group, fired the loudest shot across the bow in May 2026. The company unveiled a transparent PBM model that abandons spread pricing and list-price-linked fees in favor of fixed monthly per-member charges. Dr. Patrick Conway, CEO of Optum, said the model builds on a longstanding commitment to lowering costs and strengthening transparency by offering clients a simpler and more predictable pharmacy system. Jon Mahrt, CEO of Optum Rx and chief growth officer at Optum, said the combination of economic transparency for clients with digital tools that help patients shop for affordable options delivers a pharmacy system that is simple, easier to navigate and offers greater value.

The structural changes are specific. Optum Rx committed to passing through 100 percent of manufacturer drug rebate discounts to clients by January 1, 2028. Its group purchasing organization will transition fully to flat service fees by the end of 2027. Since the beginning of 2025, the company has eliminated 33 percent of drug reauthorizations (representing 11 percent of pharmacy prior authorizations) for a list of nearly 270 chronic condition medications. In March 2025, Optum Rx introduced pharmacy payment terms designed to reflect the actual costs pharmacies incur to deliver care; through partnerships with Pharmacy Services Administration Organizations, 100 percent of community and independent pharmacies in the Optum Rx network transitioned to these cost-based arrangements. In September 2025, the company increased brand-name drug reimbursement for 2,300 community and independent pharmacies not affiliated with a PSAO, chain or other entity.

Two digital tools accompany the pricing overhaul. ShopMyScript notifies eligible Optum Rx patients immediately after a prescription is written, providing real-time visibility into pricing, pharmacy options and delivery choices before the prescription is filled. Price Wise displays a full cost breakdown (including the drug price and a clearly defined service fee) offering an all-in price through a partner pharmacy. Consumers purchasing medications without using their benefits can see the total cost upfront, without unexpected charges at checkout. The company said the tools are intended to simplify navigation of pharmacy pricing and improve visibility into prescription costs for members and employer clients. Nancy Price, vice president of employee benefits strategic sourcing at HealthTrust, said greater transparency and predictability in pharmacy benefits helps the industry manage costs more effectively and thanked Optum Rx for being responsive and collaborative in the effort to advance pharmacy care.

The announcement comes amid growing industry and regulatory pressure on pharmacy benefit managers to increase transparency around drug pricing and rebate structures. Earlier this year, lawmakers passed PBM reform legislation aimed at tightening oversight of pricing practices across the sector. Express Scripts had also announced a shift away from rebate-based models last year, signaling broader changes in the PBM market.

Optum Rx is not a direct competitor to Turquoise Health in the hospital-and-payer rate transparency market, but its move signals that the largest buyers in healthcare now expect transparency as a baseline feature, not a differentiator.

Castlight Health has taken a different tack. The company deepened its partnership with Noom, integrating the behavior-change platform's Weight, Med (with GLP-1 support), Diabetes and Diabetes Prevention programs into Castlight's personalized health benefits platform. The integration gives employers and health plans a single entry point for cost navigation and clinical programs that target metabolic health. Castlight's platform already lets users see a breakdown of coverage and costs, discover benefits and get rewarded for engagement. The Noom deal expands the value proposition from price transparency into guided clinical action — a logical adjacent move as employers demand measurable outcomes from their transparency investments.

Healthcare Bluebook, a direct Turquoise rival in the procedure-level price transparency space, was acquired by Vālenz Health. Vālenz, a platform of integrated cost containment and payment integrity solutions, completed the acquisition to create what it calls a uniquely data-informed platform for smarter, better, faster transparent healthcare. Healthcare Bluebook's cost and quality navigation platform now sits alongside Vālenz's payment integrity and cost containment tools. CBInsights lists Healthcare Bluebook's top competitors as Turquoise Health, TALON and Tendo Care Connect; Turquoise's top competitors include Healthcare Bluebook, Tendo Care Connect and Gigasheet. The acquisition consolidates two complementary transparency assets under one roof, giving Vālenz a broader wedge into employer and payer accounts that might otherwise evaluate Turquoise as a standalone vendor.

The competitive dynamic is clear. Optum Rx is rearchitecting the PBM layer with fee-based transparency and consumer-facing price tools. Castlight is layering clinical navigation on top of cost visibility. Vālenz is rolling up procedure-level transparency into a full-stack cost containment suite. Each move expands the definition of what "price transparency" means in the market — and each raises the bar for what Turquoise must deliver to defend that base.

Where the Market Goes Next

The healthcare price‑transparency systems market is projected to grow at a 17.1% compound annual growth rate through 2030. That expansion is not abstract; it is being driven by self‑funded employers who now face fiduciary pressure to analyze the machine‑readable files which they must publish. The RAND Corporation's fifth Employer Price Transparency Study documents how plan sponsors are moving from compliance check‑boxing to active rate benchmarking. In May 2025, Aon plc launched its Health Price Transparency Analysis, an analytics tool built expressly to help U.S. employers leverage that public data. Milliman, meanwhile, markets Transparent, a service that turns transparency data into fiduciary‑grade analytics for self‑funded plans. Each new entrant signals that the employer segment (Turquoise Health's fastest‑growing customer cohort) is shifting from passive buyers to active operators of pricing intelligence.

National health expenditure underscores the urgency. CMS data cited by KPMG shows spending rose from 5% of GDP in 1960 to 17.8% in 2016, with a 19% projection for 2023 and a 20.6% target by 2034. Per‑person spending averaged a significant sum in 2024. Medicare spending alone is forecast to grow 7.7% annually through 2034, while overall national health expenditure climbs 5.4% per year — well above the 4.1% GDP growth rate. Employers absorbing those increases are adopting value‑based care models at scale; the U.S. value‑based healthcare service market expects a 7.4% CAGR through 2030. Price transparency is the prerequisite infrastructure for those models, and the platforms that turn raw MRFs into negotiable contract intelligence are becoming line‑item budget items, not pilots.

Ken Research projects healthcare occupations will generate 1.9 million openings annually during 2024‑2034, intensifying competition for clinical, technical, and administrative talent. Primary care shortage areas already cover 92 million residents (27% of the population), forcing health‑tech firms to recruit nationally. A 2023 KPMG survey found 58% of millennials and 64% of Gen Xers would switch providers for online booking capability, a consumer‑grade expectation that now permeates B2B buying committees. Companies that mandate office returns shrink their addressable talent pool precisely when the market demands rapid scaling. Turquoise's fully remote model, advertised on its own site and validated by third‑party aggregators, positions it to tap the same national labor supply that competitors like Healthcare Bluebook, Waystar, and Zelis are chasing.

Turquoise's bet is that the operating system layer — where pricing data becomes executable contract intelligence — will harden into a recurring revenue moat before the incumbents can retrofit their legacy stacks. The next 18 months will show whether the hiring boom builds that moat or just expands the talent war.

Working in frontier tech? Zero G Talent tracks the openings: see every open Turquoise Health role, browse frontier tech jobs, the companies hiring, and the people building the field.